REG - Oxford Biomedica PLC - Board Appointment

Oxford BioMedicaAnnouncement

14/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211214:nRSN5123Va&default-theme=true

RNS Number : 5123V  Oxford Biomedica PLC  14 December 2021

 

 

Oxford Biomedica Appoints Catherine Moukheibir as Non-Executive Director

Oxford, UK - 14 December 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Group"), a leading gene and cell therapy group, announces
the appointment of Ms Catherine Moukheibir to the Board as an Independent
Non-Executive Director with effect from today.

Ms Moukheibir has extensive international experience in finance, capital
markets and life sciences and is currently serving as a non-executive Board
member with various companies, both listed (Biotalys N.V., Ironwood
Pharmaceuticals, Inc), and privately-owned (CMR Surgical Limited, Asceneuron
SA, DNA Script and Noema Pharma).

Over the course of her career Ms Moukheibir, has served in senior executive
roles and Board positions including at Kymab Limited, Innate Pharma S.A,
Ablynx N.V, Genkyotex S.A, MedDay Pharmaceuticals, Zealand Pharma A/S, Zeltia
S.A., and Creabilis. Prior to that, she was the CFO of Movetis N.V, overseeing
the company's IPO on Euronext and its subsequent sale to Shire
Pharmaceuticals. She started her career in investment banking and capital
markets working in the US and London. She holds an MBA and a Masters in
Economics from Yale University.

Dr. Roch Doliveux, Chairman of Oxford Biomedica, said: "I am delighted to
welcome Catherine to the Board. Her international and impressive
diverse experience as CEO, CFO and Board member of a broad range of
healthcare companies and financial institutions will be very valuable as
we continue to strengthen our position as a life-saving cell and gene
therapy company."

Ms Catherine Moukheibir said: "I am honoured to be joining the Board of Oxford
Biomedica, a company that has contributed so much to society during the
COVID-19 pandemic whilst also continuing to gain traction as a global leader
in the gene and cell therapy space. I look forward to working with the Board
and Group."

 

Relevant disclosures

 

Ms Catherine Moukheibir is currently a Non-Executive Director of Ironwood
Pharmaceuticals, Inc. and Biotalys N.V. and in the last five years has been a
Non-Executive Director of Ablynx N.V., Cerenis Therapeutics SA, Genkyotex SA,
Orphazyme A/S and Zealand Pharma A/S.

 

There are no other disclosures required to be made in accordance with LR
9.6.13R.

 

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications: T: +44 (0)20 3709 5700

 

Mary-Jane Elliott / Matthew Neal

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a
sector leading lentiviral vector delivery platform (LentiVector®), which the
Group leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through
which it has long-term economic interests in other potential gene and cell
therapy products. Additionally, the Group has signed a 3-year master supply
and development agreement with AstraZeneca for large-scale manufacturing of
the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is
based across several locations in Oxfordshire, UK and employs more than 740
people. Further information is available at www.oxb.com (http://www.oxb.com)
 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADZMMZMFFGMZZ